Hecht Beth 4

What Happened
Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma (XERS), received equity awards and completed both withholding and an open-market sale. On Jan 30, 2026 she was granted 121,293 restricted stock units (RSUs) and 162,162 stock options (both $0 acquisition price) that vest in equal annual installments over three years. Following RSU vesting, 169,555 shares were withheld to cover tax obligations on Jan 31, 2026 (net value withheld ≈ $1,247,925 at a weighted $7.36). Separately, on Feb 2, 2026 she sold 16,667 shares in the open market for $124,147 (weighted avg reported $7.45; sales ranged $7.25–$7.59).

Key Details

• Transaction dates: Grants on Jan 30, 2026; tax-withholding/net settlement on Jan 31, 2026; open-market sale on Feb 2, 2026.
• Grants: 121,293 RSUs and 162,162 stock options (both vest over three years subject to continued service).
• Withholding for taxes: 98,375 + 46,914 + 24,266 = 169,555 shares withheld at $7.36 (total ≈ $1,247,925) to satisfy tax/remittance obligations for vested RSUs. (Filed as "Payment of exercise price or tax liability" transactions.)
• Open-market sale: 16,667 shares sold under a Rule 10b5-1 plan for proceeds of $124,147 (weighted avg $7.45; prices ranged $7.25–$7.59).
• Footnotes: RSUs/options granted under the Company’s 2018 Plan; net settlement tax withholding and 10b5-1 plan apply.
• Shares owned after transactions: Not specified in the filing.
• Filing timeliness: Form 4 filed Feb 2, 2026 — within the SEC’s two-business-day reporting window for the reported dates.

Context

• This filing shows equity compensation (RSU and option grants) and routine tax withholding (net settlement) rather than a large discretionary sale. The only open-market sale (16,667 shares) was done under a pre-established 10b5-1 plan. For retail investors, purchases or grants can signal long-term alignment; withholding and immediate sales to cover taxes are common administrative steps and do not necessarily indicate a change in insider sentiment.